110 related articles for article (PubMed ID: 24704312)
1. Is brain gliosis a characteristic of chronic methamphetamine use in the human?
Tong J; Fitzmaurice P; Furukawa Y; Schmunk GA; Wickham DJ; Ang LC; Sherwin A; McCluskey T; Boileau I; Kish SJ
Neurobiol Dis; 2014 Jul; 67():107-18. PubMed ID: 24704312
[TBL] [Abstract][Full Text] [Related]
2. Brain antioxidant systems in human methamphetamine users.
Mirecki A; Fitzmaurice P; Ang L; Kalasinsky KS; Peretti FJ; Aiken SS; Wickham DJ; Sherwin A; Nobrega JN; Forman HJ; Kish SJ
J Neurochem; 2004 Jun; 89(6):1396-408. PubMed ID: 15189342
[TBL] [Abstract][Full Text] [Related]
3. Brain vesicular acetylcholine transporter in human users of drugs of abuse.
Siegal D; Erickson J; Varoqui H; Ang L; Kalasinsky KS; Peretti FJ; Aiken SS; Wickham DJ; Kish SJ
Synapse; 2004 Jun; 52(4):223-32. PubMed ID: 15103689
[TBL] [Abstract][Full Text] [Related]
4. Why is parkinsonism not a feature of human methamphetamine users?
Moszczynska A; Fitzmaurice P; Ang L; Kalasinsky KS; Schmunk GA; Peretti FJ; Aiken SS; Wickham DJ; Kish SJ
Brain; 2004 Feb; 127(Pt 2):363-70. PubMed ID: 14645148
[TBL] [Abstract][Full Text] [Related]
5. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine.
Fitzmaurice PS; Tong J; Yazdanpanah M; Liu PP; Kalasinsky KS; Kish SJ
J Pharmacol Exp Ther; 2006 Nov; 319(2):703-9. PubMed ID: 16857724
[TBL] [Abstract][Full Text] [Related]
6. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
7. Microglial and astrocytic changes in the striatum of methamphetamine abusers.
Kitamura O; Takeichi T; Wang EL; Tokunaga I; Ishigami A; Kubo S
Leg Med (Tokyo); 2010 Mar; 12(2):57-62. PubMed ID: 20110187
[TBL] [Abstract][Full Text] [Related]
8. Brain serotonin transporter in human methamphetamine users.
Kish SJ; Fitzmaurice PS; Boileau I; Schmunk GA; Ang LC; Furukawa Y; Chang LJ; Wickham DJ; Sherwin A; Tong J
Psychopharmacology (Berl); 2009 Mar; 202(4):649-61. PubMed ID: 18841348
[TBL] [Abstract][Full Text] [Related]
9. Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.
Kish SJ; Boileau I; Callaghan RC; Tong J
Eur J Neurosci; 2017 Jan; 45(1):58-66. PubMed ID: 27519465
[TBL] [Abstract][Full Text] [Related]
10. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.
Chang L; Alicata D; Ernst T; Volkow N
Addiction; 2007 Apr; 102 Suppl 1():16-32. PubMed ID: 17493050
[TBL] [Abstract][Full Text] [Related]
11. Detection of methamphetamine neurotoxicity in forensic autopsy cases.
Kitamura O
Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S63-5. PubMed ID: 19269222
[TBL] [Abstract][Full Text] [Related]
12. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users.
Kim DJ; Roh S; Kim Y; Yoon SJ; Lee HK; Han CS; Kim YK
Neurosci Lett; 2005 Nov; 388(2):112-5. PubMed ID: 16039058
[TBL] [Abstract][Full Text] [Related]
13. The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity.
O'Callaghan JP; Martin PM; Mass MJ
Ann N Y Acad Sci; 1998 May; 844():40-9. PubMed ID: 9668663
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine.
Ares-Santos S; Granado N; Oliva I; O'Shea E; Martin ED; Colado MI; Moratalla R
Neurobiol Dis; 2012 Feb; 45(2):810-20. PubMed ID: 22115942
[TBL] [Abstract][Full Text] [Related]
15. A selective regional response of cultured astrocytes to methamphetamine.
Stadlin A; Lau JW; Szeto YK
Ann N Y Acad Sci; 1998 May; 844():108-21. PubMed ID: 9668669
[TBL] [Abstract][Full Text] [Related]
16. Brain levels of neuropeptides in human chronic methamphetamine users.
Frankel PS; Alburges ME; Bush L; Hanson GR; Kish SJ
Neuropharmacology; 2007 Sep; 53(3):447-54. PubMed ID: 17688891
[TBL] [Abstract][Full Text] [Related]
17. GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity.
Andreiuolo F; Junier MP; Hol EM; Miquel C; Chimelli L; Leonard N; Chneiweiss H; Daumas-Duport C; Varlet P
Neuropathology; 2009 Feb; 29(1):31-9. PubMed ID: 18564099
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum.
Granado N; Lastres-Becker I; Ares-Santos S; Oliva I; Martin E; Cuadrado A; Moratalla R
Glia; 2011 Dec; 59(12):1850-63. PubMed ID: 21882243
[TBL] [Abstract][Full Text] [Related]
19. Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults.
Soontornniyomkij V; Umlauf A; Soontornniyomkij B; Batki IB; Moore DJ; Masliah E; Achim CL
J Neurovirol; 2016 Oct; 22(5):650-660. PubMed ID: 27098516
[TBL] [Abstract][Full Text] [Related]
20. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats.
Escubedo E; Guitart L; Sureda FX; Jiménez A; Pubill D; Pallàs M; Camins A; Camarasa J
Brain Res; 1998 Dec; 814(1-2):120-6. PubMed ID: 9838075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
